(Q37139730)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Meropenem: a review of its use in the treatment of serious bacterial infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

Katherine A Lyseng-Williamson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Susan J Keam

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Claudine M Baldwin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

1 reference

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

803-838

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18416587%20AND%20SRC:MED&resulttype=core&format=json

Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200868060-00006

Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200868060-00006

Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200868060-00006

A Multicenter Comparative Study of Meropenem and Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections in Hospitalized Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200868060-00006

The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200868060-00006

The pharmacokinetics of meropenem in surgical patients with moderate or severe infections

21 January 2018

1 reference

12 December 2020

Prophylaxis with Meropenem of Septic Complications in Acute Pancreatitis: A Randomized, Controlled Trial Versus Imipenem

1 reference

12 December 2020

Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group

1 reference

12 December 2020

Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.

1 reference

12 December 2020

Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program

1 reference

12 December 2020

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

12 December 2020

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

1 reference

12 December 2020

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit

1 reference

12 December 2020

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

12 December 2020

Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia

1 reference

12 December 2020

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program

1 reference

12 December 2020

Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors

1 reference

12 December 2020

Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time

1 reference

12 December 2020

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

1 reference

12 December 2020

Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program

1 reference

12 December 2020

Ertapenem: a review of its use in the treatment of bacterial infections

1 reference

12 December 2020

Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).

1 reference

12 December 2020

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

12 December 2020

Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis

1 reference

12 December 2020

An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.

1 reference

12 December 2020

Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy

1 reference

12 December 2020

Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program

1 reference

12 December 2020

Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis.

1 reference

12 December 2020

Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem

1 reference

12 December 2020

Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem

1 reference

12 December 2020

Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial

1 reference

12 December 2020

Comparative review of the carbapenems

1 reference

12 December 2020

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.

1 reference

12 December 2020

Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid.

1 reference

12 December 2020

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

1 reference

12 December 2020

Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

1 reference

12 December 2020

Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer

1 reference

12 December 2020

Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients

1 reference

12 December 2020

Treatment options for multidrug-resistant Acinetobacter species

1 reference

12 December 2020

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care

1 reference

12 December 2020

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps

1 reference

12 December 2020

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

1 reference

12 December 2020

Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients

1 reference

12 December 2020

Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents

1 reference

12 December 2020

Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.

1 reference

12 December 2020

Extended-spectrum beta-lactamases: a clinical update

1 reference

12 December 2020

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial

1 reference

12 December 2020

Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial

1 reference

12 December 2020

A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections.

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

1 reference

12 December 2020

Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study

1 reference

12 December 2020

Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group

1 reference

12 December 2020

The need for antimicrobial resistance surveillance

1 reference

12 December 2020

Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations

1 reference

12 December 2020

Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy

1 reference

12 December 2020

A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.

1 reference

12 December 2020

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

12 December 2020

Best in class: a good principle for antibiotic usage to limit resistance development?

1 reference

12 December 2020

Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity

1 reference

12 December 2020

Of Pseudomonas, porins, pumps and carbapenems.

1 reference

12 December 2020

A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus

1 reference

12 December 2020

Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections

1 reference

12 December 2020

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds

1 reference

12 December 2020

Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia

1 reference

12 December 2020

Carbapenemases: the versatile beta-lactamases

1 reference

12 December 2020

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen

1 reference

12 December 2020

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

1 reference

12 December 2020

Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program

1 reference

12 December 2020

Meropenem: a review of its use in patients in intensive care

1 reference

12 December 2020

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

1 reference

12 December 2020

Practice guidelines for the management of bacterial meningitis

1 reference

12 December 2020

Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors

1 reference

12 December 2020

Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin

1 reference

12 December 2020

Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment

1 reference

12 December 2020

Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.

1 reference

12 December 2020

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

1 reference

12 December 2020

Pharmacokinetics of meropenem in animals, healthy volunteers, and patients

1 reference

12 December 2020

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

12 December 2020

Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.

1 reference

12 December 2020

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy

1 reference

12 December 2020

Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group

1 reference

12 December 2020

Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours

1 reference

12 December 2020

Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates

1 reference

12 December 2020

Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime.

1 reference

12 December 2020

A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections

1 reference

12 December 2020

Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli

1 reference

12 December 2020

Making the most of surveillance studies: summary of the OPTAMA Program

1 reference

12 December 2020

Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

1 reference

12 December 2020

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

1 reference

12 December 2020

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe

1 reference

12 December 2020

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).

1 reference

12 December 2020

Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents

1 reference

12 December 2020

Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates.

1 reference

12 December 2020

Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program

1 reference

12 December 2020

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group

1 reference

12 December 2020

Meropenem: an updated review of its use in the management of intra-abdominal infections

1 reference

12 December 2020

Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem

1 reference

12 December 2020

Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.

1 reference

12 December 2020

Intraperitoneal penetration of meropenem

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

12 December 2020

Comparative pharmacokinetics of the carbapenems: clinical implications

1 reference

12 December 2020

Guidelines for the management of adult lower respiratory tract infections

1 reference

12 December 2020

Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin

1 reference

12 December 2020

Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).

1 reference

12 December 2020

Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy

1 reference

12 December 2020

Carbapenems in serious infections: a risk-benefit assessment

1 reference

12 December 2020

Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group

1 reference

12 December 2020

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

1 reference

12 December 2020

Acinetobacter infection

1 reference

12 December 2020

Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems

1 reference

12 December 2020

Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children

1 reference

12 December 2020

Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters

1 reference

12 December 2020

Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.

1 reference

12 December 2020

Interaction between valproate and meropenem: a retrospective study

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.

1 reference

12 December 2020

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients

1 reference

12 December 2020

In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae

1 reference

12 December 2020

Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae

1 reference

12 December 2020

Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program

1 reference

12 December 2020

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).

1 reference

12 December 2020

Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study

1 reference

12 December 2020

A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women

1 reference

12 December 2020

Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results

1 reference

12 December 2020

Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group

1 reference

12 December 2020

Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).

1 reference

12 December 2020